Overview
- The Pharmacy Compounding Advisory Committee, which voted July 23–24, recommended adding six peptides—BPC‑157, MOTS‑c, KPV, TB‑500, Epitalon and Semax—to the FDA 503A bulks list while rejecting emideltide.
- Career FDA scientists told the panel the peptides lack reliable human trials and warned that safety and effectiveness have not been established for the uses proposed.
- Agency presenters said a core problem is inconsistent chemical definitions and variable composition for identically named peptides, which makes setting quality standards and dosing rules difficult.
- Several newly appointed panel members have disclosed ties to the peptide industry, raising conflict‑of‑interest concerns that critics say undercut the narrow votes and public trust.
- Even if the FDA follows the recommendation, adding these substances would require formal rulemaking that could take months to years, and the gray market for cheap, unvetted peptides with reported impurities will likely persist unless regulatory or administrative steps are taken.